These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Clinical trials and drug approvals continue to accelerate in China. Wang M Lancet Oncol; 2017 Jul; 18(7):855. PubMed ID: 28552212 [No Abstract] [Full Text] [Related]
15. An audience with Tatiana Prowell. Interviewed by Asher Mullard. Prowell T Nat Rev Drug Discov; 2014 Jun; 13(6):410-1. PubMed ID: 24875091 [No Abstract] [Full Text] [Related]
16. Is there room for improvement in adverse event reporting in the era of targeted therapies? Edgerly M; Fojo T J Natl Cancer Inst; 2008 Feb; 100(4):240-2. PubMed ID: 18270340 [TBL] [Abstract][Full Text] [Related]
17. Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials. Hucl T; Gallmeier E; Kern SE Cell Cycle; 2007 Jun; 6(11):1336-41. PubMed ID: 17568192 [TBL] [Abstract][Full Text] [Related]
18. Phase 0 clinical trials in oncology: an exploratory methodology for constructing a study with patients undergoing surgery for metastatic disease. Pocard M; Soria JC; Aldaz-Carroll L; Bellet D J Clin Oncol; 2010 Oct; 28(30):4551-3. PubMed ID: 20837954 [No Abstract] [Full Text] [Related]
19. Significance of natural product interactions in oncology. Block KI Integr Cancer Ther; 2013 Jan; 12(1):4-6. PubMed ID: 23188923 [No Abstract] [Full Text] [Related]
20. Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors. Scheulen ME; Saito K; Hilger RA; Mende B; Zergebel C; Strumberg D Cancer Chemother Pharmacol; 2012 Mar; 69(3):753-61. PubMed ID: 22020317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]